ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Futu Holdings Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FUTU

NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminder purchasers of the securities of Futu Holdings Limited (NASDAQ: FUTU) between April 27, 2020 and May 16, 2023, both dates inclusive (the “Class Period”), of the important August 11, 2023 lead plaintiff deadline, in the securities class action commenced by the Firm.

SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Futu class action, go to https://rosenlegal.com/submit-form/?case_id=16261 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose, among other things, that: (1) Futu’s business was, quite simply, illegal as it related to operations in China as a result of its failure to obtain the proper licenses; (2) it did not fully disclose to investors that it was engaging in unlawful activity and instead falsely characterized the applicable Chinese laws as ambiguous; (3) the foregoing subjected the Company to a heightened risk of regulatory enforcement; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Futu class action, go to https://rosenlegal.com/submit-form/?case_id=16261 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8867116

AROW INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Arrow Financial Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AROW

NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Arrow Financial Corporation (NASDAQ: AROW) between March 12, 2022 and May 12, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2023

SO WHAT: If you purchased Arrow securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Arrow class action, go to https://rosenlegal.com/submit-form/?case_id=17331 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose to investors that: (1) Arrow maintained defective disclosure controls and procedures and internal controls over financial reporting; (2) the foregoing increased the risk that the company could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ’s listing requirements; (3) accordingly, Arrow was at an increased risk of being delisted from the NASDAQ; (4) following the disclosure of deficiencies in the Company’s disclosure controls and procedures and internal controls over financial reporting, Arrow downplayed the severity of these issued and the associated risks; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Arrow class action, go to https://rosenlegal.com/submit-form/?case_id=17331 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8867110

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy

ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.

“We are very honored to be recognized with this award, which underlines the hard work and dedication of all of our employees to delivering quality and reliability when serving our customers,” said Philip Macnabb, CEO, Curia. “We remain steadfast in our noble purpose of improving patients’ lives, a mission that begins with our commitment to creating value for our customers.”

Frost & Sullivan noted in its report that the company’s rebrand from AMRI to Curia in 2021 put a focus on science at the center of its brand identity, highlighting a pledge to help customers advance “from curiosity to cure.” Curia has evolved over time to offer a comprehensive range of services from drug discovery through development to manufacture of both drug substance and drug product for pharmaceutical and biologics companies. The award recognizes how Curia seeks out innovative solutions by using the latest technologies to efficiently move products from discovery to development to commercial scale to accelerate speed to market for its customers. This continuous commitment to serve unspoken market needs and deliver end-to-end solutions for customers has positioned it as an industry leader.

“Curia has built its reputation by offering a best-in-class customer ownership and service experience. The company surveys clients to gauge their overall satisfaction and ensure that it is upholding the highest standards,” said Unmesh Lal, director, Healthcare & Life Sciences, Frost & Sullivan.

Each year, Frost & Sullivan employs a rigorous evaluation, measuring business and customer impact, to identify companies that consistently innovate to meet their customers’ needs while navigating new challenges and opportunities. The winner is recognized for providing a superior customer experience for overall price, performance and quality.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO’s growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8865503

Ballad Health partners with MedAware to leverage artificial intelligence platform to improve patient safety and optimize pharmacy workflows

JOHNSON CITY, Tenn., June 29, 2023 (GLOBE NEWSWIRE) — Ballad Health is partnering with Israeli-based MedAware, Ltd., to leverage artificial intelligence (AI) to improve patient safety by identifying potential medication-related errors and improving operational efficiency within the pharmacy.

MedAware’s patented AI software, coupled with data from the health system’s electronic health record, will allow for real-time evaluation of prescribed drugs against a specific and up-to-date patient profile.

MedAware’s medication safety monitoring platform runs 24/7, providing accurate and timely clinical insights at all points of medication access and delivery. Its suite of predictive and statistical models continuously analyzes prescribing patterns, accurately flagging medications that conflict with the profiles of the patient, physician and institution, thereby enabling timely interventions and education before dangerous medication-related events can occur.

“We are thrilled to partner with MedAware,” said Trish Tanner, chief pharmacy officer for Ballad Health. “This innovative technology will help us provide our patients with the highest quality of care by ensuring they receive the right medications at the right time.”

The partnership with MedAware is the direct result of the Ballad Health Innovation Center and Ballad Ventures working together to actively transform how healthcare is provided – within the Appalachian Highlands and throughout the healthcare industry.

“Our goal at the Ballad Health Innovation Center is to drive the development of innovative healthcare solutions that revolutionize the industry, while bringing innovative solutions directly to our patients,” said Bo Wilkes, managing director of the Ballad Health Innovation Center. “Innovation is the key to transforming how we provide care – especially in rural America – and we are excited about the partnership with MedAware and its very tangible potential to enhance care.”

With this implementation, MedAware will act as a safety and workflow optimization layer within Ballad Health’s electronic health record and ecosystem. MedAware’s platform complements existing tools within the electronic health record to improve the actionability and acceptance rate of medication-based alerts. As a result, hard-to-anticipate errors are caught at the earliest possible stage – avoiding dangerous and even fatal drug interactions for patients. To do so, the software utilizes advanced machine-learning algorithms that mine data gathered by millions of electronic health records to detect outliers in prescribing behavior that could potentially be harmful and immediately flag them as life-threatening.

The algorithms also mitigate high false-alarm positive rates by integrating patient-specific information into decision support that accurately detects harm in real time, so prescribers and clinical care teams can act fast and save lives.

“MedAware dramatically improves the quality of alerts,” Tanner said. “Its accuracy significantly reduces alert fatigue, exponentially increasing the quality of actionable alerts for pharmacists.”

As a result, the software therefore also enables substantial savings in time and effort for pharmacists and providers.

“We are excited to partner with Ballad Health and look forward to working together to mitigate medication-related risks while improving pharmacy workflow efficiencies. MedAware’s AI-based data-driven solution was designed to mitigate these issues while providing substantial clinician satisfaction,” said David Franklin, CEO of MedAware.

Each year, nearly 8 million people in the United States are exposed to serious and preventable prescription errors. Of those, 7,000 to 9,000 people tragically die because of a medication error, according to a 2021 study published in the National Library of Medicine. An industry faced with a stressed physical and emotional state – which has been exacerbated by the novel coronavirus (COVID-19) pandemic – can lead to more medication errors, as well, which has resulted in demand for an advanced decision support system, like MedAware, to help mitigate the risks of potentially harmful or fatal prescribing errors.

“MedAware is needed, it’s innovative, it’s life-saving, and we’re honored to add it to the Ballad Health ecosystem,” Tanner said. “Not only will it start making a difference for our patients from day one, but thanks to its algorithmic nature, it will require minimal human resources to maintain. Our pharmacists and caregivers will do the same excellent work they already do, but with this major safeguard in the background. It’s a game-changer in frontline healthcare delivery.”

MedAware is just one of several projects the Ballad Health Innovation Center and Ballad Ventures, Ballad Health’s venture capital subsidiary, are pursuing that are intended to enhance patient care and have the potential to reach patients and healthcare delivery systems nationally and worldwide. More information is available at https://balladventures.com/.

About Ballad Health
Ballad Health is an integrated community health improvement organization serving 29 counties of the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, Northwest North Carolina and Southeast Kentucky. Our system of 21 hospitals, post-acute care and behavioral health services, and a large multi-specialty group physician practice works closely with an active independent medical community and community stakeholders to improve the health and well-being of close to one million people. By leading in the adoption of value-based payments, addressing health-related social needs, funding clinical and health systems research and committing to long-term investments in strong children and families in our region, Ballad Health is striving to become a national model for rural health and healthcare.

About MedAware
MedAware’s medication safety monitoring platform lives within existing technology systems, EHRs, and devices to identify dangerous medication-related risks throughout the entire patient journey. By applying a personalized look at the appropriateness of a patient’s medication therapy at each stage of their treatment journey, MedAware’s technology can alert care teams to potential harm sooner than traditional tools—streamlining existing workflows, saving clinical time, and enabling intervention before harm occurs.

Ashlea Ramey
Ballad Health
423-863-2383
ashlea.ramey@balladhealth.org

GlobeNewswire Distribution ID 8866426

Legacy, Storytelling and Community: How INVNT.ATOM™, [INVNT GROUP]’s digital innovation agency, transformed Automobili Lamborghini’s global brand footprint with its Web3 initiatives

INVNT.ATOM collaborated with the legendary automotive brand to launch two successful Web3 campaigns across 12 months, invigorating the iconic brand’s leadership in innovation, art and design.

Singapore, June 28, 2023 (GLOBE NEWSWIRE) — Across 2022 and 2023, INVNT.ATOM™, [INVNT GROUP]™’s digital and Web3 Innovation division delivered two historic NFT campaigns in collaboration with Automobili Lamborghini, as the legacy super sportscar leader celebrated their 60th anniversary and entered its hybrid era.

With global features in media outlets such as Forbes, Fast Company, Be in Crypto, and an announcement from Lamborghini’s CEO Steve Winkelmann that Lamborghini’s sports cars are sold out until 2024, [INVNT GROUP] has concluded two back to back campaigns in partnership with Automobili Lamborghini.

‘Lamborghini Ultimate’ a world first 1:1 NFT & The Last Aventador Coupé in collaboration with contemporary artist Krista Kim and Grammy award winning artist Steve Aoki, and most recently “The Epic Road Trip”, an 8-month Web3 initiative with utilities which cultivated a community of global Web3 loyalists around the world. The conclusion of “The Epic Road Trip” marked the brand’s 60th anniversary where the Italian marque revealed the “Revuelto”, the brand’s first dual-powertrain supercar – continuing their commitment to a more sustainable future.

Lamborghini was the first super sports car  brand to enter the world of digital collectibles, with their release of digital bitstamps in 2020. In partnership with [INVNT GROUP], two major Web3 initiatives have followed suit, cultivating a new community of a younger tech audience, and established loyalists to mark the hybrid era, as the brand races towards complete electrification by 2030.

[INVNT GROUP] partnered with Steve Aoki and Krista Kim to create an audiovisual collaboration which saw the creation of the world’s first 1:1 NFT supercar, auctioning off the physical version of the last ever Aventador Coupe with auction house RM Sotheby’s. The NFT paired with the physical sports car sold at an auction price of $1.6M, placing the purchase price in the top 10 new Lamborghinis ever sold.

On the back of the global success and impact of“Lamborghini Ultimate” Lamborghini continued their partnership with [INVNT GROUP] with the launch of “The Epic Road Trip”. This 8-month long campaign showcased monthly prizes and NFT reveals, concluding in a global celebration of the brand’s 60th anniversary and the ultimate reveal of the Revuelto. The consequential results of “The Epic Road Trip ” showcased a nod to the brand’s transformation, with 10.5x campaign ROI. Collectively, both campaigns have garnered 1.8 billion global editorial media impressions, across 2.4K featured editorial placements, totalling over $17.3M USD of advertising value.

“These results demonstrate how incredibly powerful leveraging Web3 is in any modern marketing strategy,” says Scott Cullather,  President & CEO of [INVNT GROUP], and CEO of INVNT.ATOM, “These are highly engaged, hands-on collectors with a passion for the Lamborghini brand. By focusing on a curated group of brand loyalists, Lamborghini was able to both deepen its connection with its biggest fans while also welcoming new people to be a part of its timeless heritage and future. As an ultra-luxury brand that sold just 9,233 vehicles in 2022, every boost in purchase intent is worth millions.”

“Lamborghini is an aspirational brand, and Web3 is a bridge to people that are dreaming Lamborghini, but also for people that are not familiar with the brand and more familiar with art, design and NFTs. It’s an example of how art and design are connected to our brand. And the good thing is that with the NFTs we’re able to make sure that this dream is also in the reach for the fan,” said Christian Maestro, Marketing Director of Automobili Lamborghini, in Carly Reilly’s Overpriced JPEGS Podcast Series with Scott Cullather.

As the brand continues its journey towards complete hybridization of its lineup by 2025, expect further experimentation at the leading edge of community, blockchain and utility.

Driven by [INVNT GROUP]’s “Challenge Everything” mantra backed by world-class storytelling, both campaigns immersed the legacy brand into the world of Web3, whilst also adopting elements of the physical world into the journey. The phygital experiences, told a tale of brand transformation, as Lamborghini fans are given brand new avenues to engage with the legacy brand into the future.

About INVNT.ATOM™ INVNT.ATOM, part of [INVNT GROUP] THE GLOBAL BRANDSTORY PROJECT™, is an innovation and brand experience agency devoted to helping global brands chart a course, navigate, activate, and create new opportunities at the digital frontier of Web3. Headquartered in Singapore, the collective of strategists, marketers, creators, programmers, matchmakers, and thought leaders, turn strategies into stories and stories into experiences that engage communities on the global stage. For more information about INVNT.ATOM, visit: www.invntatom.com.

About [INVNT GROUP]™ [INVNT GROUP] was established as an evolution of the founding global live brand storytelling agency INVNT. Led by President and CEO, Scott Cullather, [INVNT GROUP], THE GLOBAL BRANDSTORY PROJECT™ represents a portfolio of disciplines designed to help forward-thinking organizations innovate and impact audiences everywhere. The GROUP consists of modern brand strategy firm, Folk Hero; creative-led culture consultancy, Meaning; production studio & creative agency, HEVĒ; events for colleges and universities, INVNT Higher Ed; digital innovation division, INVNT.ATOM; creative multimedia experience studio, Hypnogram; and the original live brand storytelling agency, INVNT. For more information visit www.invntgroup.com.

Media Kit (High-res imagery and videos)

Attachment

Paola Cracknell
INVNT.ATOM
+61 452 452 051  
pcracknell@invnt.com

Jhonathan Mendez De Leon
[INVNT GROUP]
+1 347 819 2089
jmendezdeleon@invnt.com

GlobeNewswire Distribution ID 8866009